Using mHealth to Improve Adherence and Reduce Blood Pressure in Individuals With Hypertension and Mood Disorders

Launched by CASE WESTERN RESERVE UNIVERSITY · Dec 15, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help people with high blood pressure who also have mood disorders like Bipolar Disorder or Major Depressive Disorder. The researchers want to see if using a combination of personalized support and self-monitoring can help these individuals stick to their blood pressure medication better than just keeping track of their own blood pressure. The goal is to improve how well participants manage their medication and lower their blood pressure, which can lead to better health outcomes.

To participate in this study, individuals must be between 21 and 80 years old, have a diagnosis of either Bipolar Disorder or Major Depressive Disorder, and have high blood pressure (a reading of 130 or higher). They should also have been prescribed blood pressure medication for at least three months and have experienced difficulties taking it as directed. Participants will need their own cell phone for text messages related to the study. It's important to note that people at high risk for suicide or those who cannot communicate in English will not be included in the trial for safety reasons. Throughout the study, participants can expect to receive support and guidance to help them manage their health better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age range: from 21 to 80
• • Have a clinical diagnosis of either Bipolar Disorder or Major Depressive Disorder as determined by a standardized diagnostic interview, the Mini-International Neuropsychiatric Interview (MINI)
• • Have elevated systolic blood pressure ≥130 at screening at least 2 different times during the screening period
• • Have received a diagnosis of hypertension per patient self-report at least 6 months prior to enrollment
• • Have been prescribed at least one regularly scheduled antihypertensive medicine for 3 or more months since diagnosis
• • Have difficulty with adherence to prescribed antihypertensive medication currently or in the past based on one of the following questions: Do you ever miss doses of your prescribed medications for high blood pressure? Or b. Do you ever try to manage your high blood pressure on your own without medication?
• • For those with MDD, currently being prescribed an antidepressant medication
• • Have their own cellular phone in order to receive text messages as part of the intervention
• Exclusion Criteria:
• • Unable/unwilling to participate in psychiatric interviews. This will include individuals, who may be too psychotic to participate in interviews/rating scales
• • Unable/unwilling to give written, informed consent to study participation
• • In the interest of patient safety, individuals who are at high immediate risk for suicide will be excluded from study participation. The suicide risk assessment will be informed by standardized assessments of psychiatric symptoms, the Mini-International Neuropsychiatric Interview (MINI), and the Montgomery Asberg Depression Rating Scale (MADRS). Individuals with active suicidal ideation and recent suicide attempt or current intent and plan will be excluded from study participation. Individuals who score a ≥ 5 on item 10 of the MADRS will be considered to be at high risk for suicide, although individuals with MADRS scores lower than 5 could potentially be excluded if either the psychologist or psychiatrist PIs believe that the individual is at high immediate risk for suicide based upon other input or information. In the event that a potential study participant is determined to be at high risk for suicide, that individual will not be enrolled and the study staff will immediately implement procedures for the safety of the individual. Once that individual is no longer at risk, they may be rescreened for possibility enrollment in the study
• • Individuals who are monolingual, non-English speaking will be excluded. Given the proposed sample sizes of the iTAB-CV + SM and SM alone treatment arms in the proposed study, it would not be practical to conduct sub-group analyses. Based upon our BD adherence work and RCT, which drew upon a population similar to the proposed trial, there were no potential subjects who were excluded from the studies due to inability to speak English. Hispanic individuals made up 3.6% of those enrolled
• • Upper arm circumference \> 50cm